American Heart Journal
Volume 151, Issue 2 , Pages 282-287 , February 2006

Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trials

  • B-Vitamin Treatment Trialists' Collaboration

      Affiliations

    • Authors members and collaborators are listed at Appendix A.
    • Reprint requests: Robert Joseph Clarke, MD, MRCP, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Clinical Medicine, Radcliffe Infirmary, OX2 6HE Oxford, UK. E-mail: robert.clarke@ctsu.ox.ac.uk

Received 25 November 2004 ,Accepted 26 April 2005.

References 

  1. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386–389
  2. Mudd SH, Levy HL, Kraus JP. Disorders of transulfuration. In: The metabolic and molecular bases of inherited disease. 8th ed.. New York: McGraw-Hill; 2001;p. 2007–2056
  3. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693–2698
  4. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015–2022
  5. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ. 1998;316:894–898
  6. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449–1454
  7. Bostom AG, Jacques PF, Liaugaudas G, et al. Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid–fortified cereal grain flour. Arterioscler Thromb Vasc Biol. 2002;22:488–491
  8. Clarke R, Collins R. Can dietary supplements with folic acid or vitamin B-6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk. 1998;5:249–255
  9. Boushey C, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057
  10. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk. 1998;5:229–232
  11. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–113
  12. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:2023–2031
  13. Baker F, Picton D, Blackwood S, et al. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial. Circulation. 2002;A3642
  14. Spence JD, Howard VJ, Chambless LE, et al. Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design. Neuroepidemiology. 2001;20:16–25
  15. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–575
  16. VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) trial: rationale and design of an international large, simple, randomized trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischemic attack or stroke. Cerebrovasc Dis. 2002;13:120–126
  17. Bassuk SS, Albert CM, Cook NR, et al. The Women's Antioxidant Cardiovascular Study: design and baseline characteristics of participants. J Women's Health. 2004;13:99–117
  18. Galan P, de Bree A, Mennen LI, et al. Background and rationale of the Su.Fol.Om3 study: double blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamins B6 and B12 and or omega 3 fatty acids on the prevention of recurrent ischaemic events in subjects with atherosclerosis in the coronary or cerebral arteries. J Nutr Health Aging. 2003;6:430–437
  19. Bleie O, Refsum H, Ueland PM, et al. Changes in basal and post-methionine load concentrations of total homocysteine and cystathionine after B vitamin intervention. Am J Clin Nutr. 2004;80:641–648
  20. Lindholm A, Albrechtsen D, Frodin L, et al. Ischemic heart disease: major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation. 1995;60:451–457
  21. Kasiske BL, Guijarro C, Massy Z, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol. 1996;7:158–165
  22. Arend SM, Mallat JK, Westendorp RJW, et al. Patient survival after renal transplantation; more than 25 years of follow-up. Nephrol Dial Transplant. 1997;12:1672–1679
  23. Beaulieu AJ, Gohh RY, Han H, et al. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscler Thromb Vasc Biol. 1999;19:2918–2921
  24. Machin D, Cambell MJ. Statistical tables for the design of clinical trials. Oxford: Blackwell Scientific Publications; 1997;
  25. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22

 The study was supported in part by grants from the British Heart Foundation, London, England, and the Medical Research Council, London, England, and the European Union BIOMED Program (BMH4-98-3549), Brussels, Belgium.

PII: S0002-8703(05)00444-8

doi: 10.1016/j.ahj.2005.04.025

American Heart Journal
Volume 151, Issue 2 , Pages 282-287 , February 2006

Article Tools